IRON - Disc Medicine, Inc.

69.08
-2.330   -3.373%

Share volume: 275,229
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$71.41
-2.33
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.82%
1 Month
20.81%
3 Months
-4.65%
6 Months
-17.13%
1 Year
69.78%
2 Year
31.12%
Key data
Stock price
$69.08
P/E Ratio 
0.00
DAY RANGE
$68.52 - $71.96
EPS 
-$5.50
52 WEEK RANGE
$40.00 - $99.50
52 WEEK CHANGE
$62.26
MARKET CAP 
2.998 B
YIELD 
N/A
SHARES OUTSTANDING 
38.160 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$351,706
AVERAGE 30 VOLUME 
$419,788
Company detail
CEO: Georges Gemayel
Region: US
Website: geminitherapeutics.com
Employees: 30
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Gemini Therapeutics, Inc. engages in developing therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) Its lead candidate is GEM103, a recombinant form of the human complement factor H protein. The company also develops GEM307 for treatment of systemic diseases.

Recent news